The Post-Partisan Emporium

Replicon: Big Pharma Preps the Next Bioweapon The Corbett Report by James Corbett We've all heard of mRNA "vaccines" by now. In fact, no matter where you are in the world and no matter how switched on to Big Pharma and its scamdemic tricks you may be, you doubtless know people who took the mRNA jab. Perhaps you were even coerced into it yourself. But have you heard about the  next  generation of "vaccines" that Big Pharma is preparing to unleash upon the public? They're called sa-mRNA vaccines, or "replicon" vaccines, and they've already been approved in Japan, where they are expected to start rolling out as early as next month. If you're concerned about the dangers of the mRNA "vaccines," you should be  very  concerned about the threat posed by these new experimental replicon "vaccines." Let's examine the details. MEET THE REPLICONS Image courtesy of  this article . Don't mind the typo in the image title! (Trust

 I thought it was a joke... But no! It is really there .

  Hey, Elon: If You Want to Invest in Biotech, Learn Some Bio! The entire biotechnology endeavor needs to take a huge step back - show some humility, admit how little we know, and stop pushing out dangerous and deadly products. Debbie Lerman Illustration by  Anthony Freda In a recent article entitled “ Elon Musk’s Love Affair with mRNA ,” Substacker and journalist Robert Kogon noted that Elon Musk has invested in “mRNA technology” since before Covid, when Musk’s Tesla partnered with the German mRNA company CureVac to produce so-called “RNA printers”: an automated system for manufacturing mRNA and mRNA-based drugs. Musk enthusiastically tweeted about his investment, and his general belief in the medical potential of lab-made genetic products back in 2020 and again four years later: July 2, 2020 “ This [synthetic RNA and DNA] basically makes the solution to many diseases a software problem ”  May 8, 20204   “ Synthetic mRNA is basically digital medicine with incredible potentia l”  In be

  The WHO: Building a Permanent Pandemic Market In the face of a potentially industry-ending slew of patent cliffs, Big Pharma has begun acquiring biotechnology companies to stave off collapse. To get these drugs to market, the industry is pursuing the only solution left for their dying model: a full takeover of the WHO to capture the global regulatory system. BY MAX JONES Big Pharma must soon confront an industry-wide hazard that reaches magnitudes far greater than the typical concerns of corporate profit margins and business politics. Through years of industry consolidation, it has essentially made itself “too big to fail.” Only now, the model which it once could never fail within — that is, the practice of obtaining patent exclusivity over drugs that are approved through clinical trials and regulations — has become obsolete, even impossible, under the current conditions of the industry.  In this new climate, the trials and regulations Big Pharma once successfully navigated may very